Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sabarubicin - Menarini Pharmaceuticals

Drug Profile

Sabarubicin - Menarini Pharmaceuticals

Alternative Names: BMS 195615; MEN-10755

Latest Information Update: 28 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Menarini
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action Apoptosis stimulants; Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Feb 2020 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Second-line therapy or greater) in China (IV, Infusion)
  • 06 Feb 2018 Sabarubicin is still in clinical development for Small cell lung cancer (Menarini Pharmaceuticals website, February 2018)
  • 09 Sep 2015 No recent reports on development was identified - Phase-II for Solid tumours in Europe (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top